J0208 Injection, pedmark, 100 milligrams
Also known as: amifostine mesylate, Pedmark
Amifostine mesylate (Pedmark) injection 100 milligrams, a cytoprotective agent for cisplatin ototoxicity.
In Plain Language
hearing protection during chemotherapy; ototoxicity prevention
Clinical Context
Intravenous amifostine formulation (Pedmark) specifically for reducing cisplatin-related ototoxicity (hearing loss) in pediatric patients with cancer.
RVU Information
CPT J0208 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J0208?
CPT J0208 (Injection, pedmark, 100 milligrams) is a J Codes (Drugs) code. Amifostine mesylate (Pedmark) injection 100 milligrams, a cytoprotective agent for cisplatin ototoxicity.
How is J0208 administered?
CPT J0208 is administered by a healthcare provider, typically via injection or infusion. Intravenous amifostine formulation (Pedmark) specifically for reducing cisplatin-related ototoxicity (hearing loss) in pediatric patients with cancer. It is used by Oncology, Pediatrics.
When is CPT J0208 used?
Intravenous amifostine formulation (Pedmark) specifically for reducing cisplatin-related ototoxicity (hearing loss) in pediatric patients with cancer.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.